Actinium Pharmaceuticals, Inc.
ATNM · AMEX
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $1 | $1 |
| % Growth | -100% | -92.1% | -10% | – |
| Cost of Goods Sold | $1 | $0 | $0 | $1 |
| Gross Profit | -$1 | $0 | $1 | $1 |
| % Margin | – | 100% | 100% | 54.2% |
| R&D Expenses | $30 | $39 | $23 | $18 |
| G&A Expenses | $12 | $13 | $12 | $0 |
| SG&A Expenses | $12 | $13 | $12 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1 | $0 | $0 | $0 |
| Operating Expenses | $41 | $52 | $35 | $26 |
| Operating Income | -$42 | -$52 | -$34 | -$25 |
| % Margin | – | -64,098.8% | -3,311.1% | -2,182.2% |
| Other Income/Exp. Net | $4 | $3 | $1 | $0 |
| Pre-Tax Income | -$38 | -$49 | -$33 | -$25 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$38 | -$49 | -$33 | -$25 |
| % Margin | – | -60,269.1% | -3,205.5% | -2,165.6% |
| EPS | -1.27 | -1.83 | -1.37 | -1.2 |
| % Growth | 30.6% | -33.6% | -14.2% | – |
| EPS Diluted | -1.27 | -1.83 | -1.37 | -1.2 |
| Weighted Avg Shares Out | 30 | 27 | 24 | 21 |
| Weighted Avg Shares Out Dil | 30 | 27 | 24 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $4 | $3 | $1 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$37 | -$51 | -$33 | -$24 |
| % Margin | – | -63,123.5% | -3,243.2% | -2,119.8% |